Overview

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a non-blinded, non-randomized pharmacokinetic study to determine the oral bioavailability of clofarabine, and the effect of cimetidine on clofarabine pharmacokinetics in patients with poor-risk acute leukemias and myelodysplastic syndrome (MDS).
Phase:
Phase 1
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Cimetidine
Clofarabine